
Acute Pulmonary Embolism Prof.Ali .Kassem **Internal Medicine Department** Sohag Faculty of Medicine



Pulmonary circulation





Source

- DVT
- IEC of the right side of heart
- Air embolism
- Fat embolism
- Amniotic fluid embolism
- Septic embolism
- Tumor embolism

Risk Factors

- Prior DVT or PE
- Congestive Heart Failure
- Malignancy
- Obesity
- smoking
- Estrogen, OCP, HRT
- Pregnancy
- Lower limbs injury
- Orthopedic Surgery
- Prolonged immobilization, travel
- Surgery requiring > 30 minutes general anesthesia



Risk Factors Cont'd

- Age > 40
- Venous Stasis
- Factor V Leiden mutation
- Protein C deficiency
- Protein S deficiency
- Antithrombin deficiency
- Prothrombin G20210A mutation
- Anticardiolipin antibodies
- SLE, APS
- Hyperhomocystinemia



Clinical Presentation

- Small PE: Asymptomatic, SOB, chest discomfort.
- Medium PE: SOB, Haemoptysis, Pleuritic chest pain, Tachycardia, Tachypnea, Pleural rub.
- Massive PE: Death, Shock, Severe central chest pain, Syncope, Pallor, Sweating, Central cyanosis, Elevated JVP, Loud P2, S2 split, gallop rhythm.
- DVT



Differential Diagnosis

- Myocardial Infraction
- Pleurisy
- Pneumonia
- Bronchitis
- Pneumothorax
- Costochondritis
- Rib #



Investigations

Laboratory:


CBC, Coagulation profile, ESR, LDH, ABG

D-dimer:

- Sensitive but not specific
- Up to 80% of ICU patients have elevated Ddimer in the absence of VTE
- More than 500 Mg/mL


Alveolar-Arterial O2 Gradient

- A-a O2 gradient = PaO2 (alveolar) PaO2 (arterial)
- Gradient > 15-20 is considered abnormal.





ECG





Imaging Investigations

Table 8. Chest X-Ray Findings In Patients With Pulmonary Embolism.

Atelectasis

Parenchymal infiltrates

Elevated diaphragm (both unilateral and bilateral)

Enlarged hilum

Enlarged mediastinum

Cardiomegaly (in chronic PE)

Pleural effusion

Oligemia (Westermark's sign)

Prominent central pulmonary artery (Fleischner sign)

Pleural-based area of increased opacity (Hampton's hump)


Pulmonary edema

18



20/01/2016

Westermark's sign





Lower limb venous system Ultrasonography & Doppler






CT Pulmonary Angiography







Pulmonary Angiography





Other Tests

- Echocardiography
- Cardiac troponin



Management

- Emergency management
- Further management: Anticoagulation, Thrombolysis,

Resuscitation

- ABC
- Oxygen 100%
- IV access. Send baseline bloods, including clotting profile. Perform ECG
- Analgesia: Pethidine, Morphine 5-10 mg IV
- Management of cardiogenic shock (fluids and inotropes- Dobutamine)

Thrombolytic Therapy

Streptokinase, Urokinase, Alteplase
 ,Recombinant tissue plasminogen activator

Streptokinase 250,000 U over 30 mins

 Aim to: Relieve pulmonary vasculature obstruction, Improve right ventricular efficacy, Correct the hemodynamic instability.



Anticoagulant Therapy

Heparin

- 5000-10000 Units IV Loading Dose
 Then 1000 Units/hr IV infusion drip
- Duration: 7-10 days OR till clinical improvement
- Follow up by PTT (1.5-2.5)





Anticoagulant Therapy cont'd

- Warfarin
- 2.5-7.5 mg/day Orally
- Started with Heparin (5-7 days to start acting)
- Duration: 3-6 months
- Monitor INR (2-3)





Initial Treatment Extended Treatment Long-Term Treatment Vitamin K antagonists Vitamin K antagonists Unfractionated heparin (INR target, 2.0-3.0) (INR target, 2.0-3.0 or 1.5-1.9) Low-molecular-weight heparin Recurrent PF Fondaparinux or PE and uncured Thrombolysis cancer: Percutaneous mechanical embolectomy Surgery Vitamin K antagonists ≥5 Days

≥3 Mo






New oral anticoagulants (NOAK) Direct oral anticoagulants (DOAK)



Embolectomy


- Surgical Embolectomy
- Catheter Embolectomy
- Massive life-threatening PE



20/01/2016



Recurrent DVT & PE: Vena cava filter





20/01/2016



Prevention

- Prophylaxis is the single most important measure for ensuring patient safety in hospitalized patients
- Compressive stockings, Aspirin, Anticoagulation
- Management of risk factors
- Follow up



